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Pentavalent antimonials have been the first-line treatment for leishmaniasis for decades. However, the development of resis-
tance to sodium stibogluconate (SSG) has limited its use, especially for treating visceral leishmaniasis (VL). The present work
aims to optimize a cationic liposomal formulation of SSG for the treatment of both SSG-sensitive (AG83) and SSG-resistant
(GE1F8R and CK1R) Leishmania donovani infections. Parasite killing was determined by the 3-(4,5-dimethylthiazol-2)-2,5-di-
phenyltetrazolium bromide (MTT) assay andmicroscopic counting of Giemsa-stained macrophages. Macrophage uptake studies
were carried out by confocal microscopic imaging. Parasite-liposome interactions were visualized through transmission electron
microscopy. Toxicity tests were performed using assay kits. Organ parasite burdens were determined bymicroscopic counting
and limiting dilution assays. Cytokines were measured by enzyme-linked immunosorbent assays (ELISAs) and flow cytometry.
Although all cationic liposomes studied demonstrated leishmanicidal activity, phosphatidylcholine (PC)-dimethyldioctadecyl-
ammonium bromide (DDAB) vesicles were most effective, followed by PC-stearylamine (SA) liposomes. Since entrapment of
SSG in PC-DDAB liposomes demonstrated enhanced ultrastructural alterations in promastigotes, PC-DDAB-SSG vesicles were
further investigated in vitro and in vivo. PC-DDAB-SSG could effectively alleviate SSG-sensitive and SSG-resistant L. donovani
infections in the liver, spleen, and bone marrow of BALB/c mice at a dose of SSG (3 mg/kg body weight) not reported previously.
The parasiticidal activity of these vesicles was attributed to better interactions with the parasite membranes, resulting in direct
killing, and generation of a strong host-protective environment, necessitating a very low dose of SSG for effective cures.
Visceral leishmaniasis (VL), caused by the protozoan parasiteLeishmania donovani, results in 0.2 to 0.4 million cases re-
ported annually and poses a threat to about 200 million people
worldwide. With the advent of the human immunodeficiency vi-
ruses, VL has surged as an opportunistic infection among AIDS
patients (1). Pentavalent antimonial drugs are the first-line drugs
against all forms of leishmaniasis, although their use for the treat-
ment of VL has been discontinued in India due to the emergence
of resistance. Extended treatment regimens, parenteral adminis-
tration, and toxic side effects limit patient compliance with treat-
ment. Frequent therapeutic failures due to resistance to the anti-
monial drug sodium stibogluconate (SSG) necessitate the use of
second-line drugs such as amphotericin B (AMB), which aremore
toxic. Alternate therapies for VL have resulted in the development
of several lipid- and liposome-based formulations of conventional
drugs, with enhanced efficacies and reduced toxicities (2–7). The
advantages of the use of liposomes as drug delivery vehicles for
treating macrophage-resident parasites such as Leishmania in-
volve their ease of preparation, low toxicity, and biodegradability
and the natural liposome homing sites in macrophages of the re-
ticuloendothelium system (8). Their efficacies, however, depend
on several physical parameters, including size, phospholipid com-
position, vesicle stability, and most importantly, surface charge
(9–13). Various studies with differentially charged liposomes in-
dicate increased uptake and thus enhanced homing of cationic
liposomes, in comparison to neutral or anionic liposomes, to den-
dritic cells and macrophages (14–17). In addition, we reported
earlier that cationic liposomes bearing egg phosphatidylcholine
(PC) and stearylamine (SA) (i.e., PC-SA) had direct killing activity
against various strains of Leishmania, an activity not observed
with anionic or neutral liposomes (18, 19). Encapsulation of a
suboptimal dose of SSG within these cytolytic vesicles (i.e., PC-
SA-SSG) further enhanced the therapeutic potential of either of
the monotherapies, as single-dose treatments against both SSG-
responsive and non-SSG-responsive established murine VL (20,
21). The aim of antileishmanial therapy is to achieve maximum
efficacy withminimumdoses of the drug and carrier for a success-
ful cure. Therefore, we investigated the potential leishmanicidal
activity of cationic liposomes, composed of various cationic lipids,
against both SSG-sensitive and SSG-resistant L. donovani para-
sites, in the search for an optimal formulation of SSG to treat a
nonhealing murine model of VL.
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MATERIALS AND METHODS
Materials.Cetyltrimethylammonium bromide (CTAB), dodecyltrimeth-
ylammonium bromide (DTAB), dimethyldioctadecylammonium bro-
mide (DDAB), dioleoyloxytrimethylammonium propane (DOTAP), and
egg PC were purchased from Sigma-Aldrich (St. Louis, MO). SA was
purchased fromFluka (Buchs, Switzerland) (Table 1). SSGwas purchased
from Gluconate Health Ltd. (Kolkata, India). Medium 199 (M199) and
RPMI 1640mediumused in the experimentswere purchased fromSigma-
Aldrich. Both fetal bovine serum (FBS) and antibiotics (penicillin-strep-
tomycin) were Gibco products from Invitrogen Corp. Assay kits for per-
forming toxicity tests (serum urea, creatinine, serum glutamate pyruvate
transaminase [SGPT], and serum alkaline phosphatase [ALP] assays)
were from Dr. Reddy’s Laboratories Ltd. (Hyderabad, India). 3-(4,5-Di-
methylthiazol-2)-2,5-diphenyltetrazolium bromide (MTT) was fromMP
Biomedicals, LLC (Solon, OH). All other chemicals were of analytical
grade.
Animals and parasites. BALB/c mice (approximately 25 g), 4 to 6
weeks of age, were used for in vivo studies, in accordance with standard
procedures approved by the Animal Ethics Committee of the Indian In-
stitute of Chemical Biology (protocol 147/1999/CPCSEA) under the
Committee for the Purpose of Control and Supervision of Experiments
on Animals (CPCSEA), Ministry of Social Justice and Empowerment,
Government of India. The Leishmania donovani isolates AG83 (MHOM/
IN/83/AG83), GE1F8R (derived from GE1; MHOM/IN/89/GE1), and
CK1R (clinical isolate, isolated as MHOM/IN/1995/CK from a non-SSG-
responsive patient) (21) were maintained by serial passage in hamsters.
Amastigotes were isolated from infected spleens and allowed to transform
to promastigotes by cultivation at 22°C in complete medium, i.e., M199
(pH 7.4) supplemented with 20% heat-inactivated FBS, 2 mM glutamine,
25 mM HEPES, 100 IU/ml penicillin, and 100 g/ml streptomycin.
Preparation of liposomes.Cationic liposomes were prepared with 20
mg of egg PC with CTAB, DTAB, DDAB, DOTAP, or SA (Table 1) at a
molar ratio of 7:2, as reported previously (21), and were desiccated over-
night. The thin dry films were dispersed in 1 ml of 20 mM phosphate-
buffered saline (PBS). For drug entrapment, lipid films containing PC-SA
or PC-DDAB were dispersed in 20 mM PBS containing 1 mg/ml of SSG.
For fluorescent labeling of liposomes, rhodamine B was dissolved at 0.1
mg/ml with the lipids, and the following day the films were dispersed in
PBS containing 5-carboxyfluorescein (0.1 mg/ml). The mixtures were
vortex mixed, and the suspensions were sonicated for 30 s in an ultra-
sound probe sonicator, followed by incubation for 2 h at 4°C. Unencap-
sulated SSG or dye was separated from the liposomes by three successive
centrifugations at 30,000 g for 30 min each at 4°C (20). The encapsula-
tion efficiency values for SSG within PC-SA-SSG and PC-DDAB-SSG
liposomes, as measured by atomic absorption spectroscopy (AAS), were
60% and 65%, respectively (22). The PC/SA/SSG and PC/DDAB/SSG
molar ratios were 7:2:0.4 and 7:2:0.6, respectively.
Physicochemical characterization of liposomes. The average diame-
ters of liposomes were determined in appropriately diluted liposome sus-
pensions using photon correlation spectroscopy with a Nano Zs Zeta-
Sizer system (Malvern Instruments,Worcestershire, UnitedKingdom), as
described earlier (23). The electrophoretic mobilities and zeta potentials
of the complexes were measured using a Zetaplus zeta potential analyzer
(Brookhaven Instruments Corp., Holtsville, NY). Small aliquots from the
different cationic liposomal preparations, prepared as described above
but in 20 mM phosphate buffer without saline, were diluted to an appro-
priate volume with the same buffer, and the zeta potentials andmobilities
of the particles were measured at 25°C (23).
Effects on L. donovani promastigotes. To investigate the effects of
cationic liposomes on promastigotes freshly transformed from amasti-
gotes of L. donovani AG83, GE1F8R, or CK1R, 2 106 parasites/ml sus-
pended in complete medium were incubated with graded concentrations
(8.85 to 212 M) of cationic liposomes for 1 h at 37°C (18). The control
parasites were incubated with 0.01% Triton X-100. Following treatment,
the tubeswerewashedwith PBS. The pellets were resuspended in 100l of
a solution of 2mg/mlMTT in PBS, and themixtures were incubated for 4
h at 22°C. The reduced formazan, which is a measure of cell viability, was
dissolved in dimethyl sulfoxide. The absorbance at 550 nmwas measured
in a spectrophotometer (Hitachi Electronics, Japan) (24).
Effects on parasite-infected macrophages. Peritoneal macrophages
from naive BALB/c mice were isolated and cultured at 37°C with 5% CO2
in RPMI 1640 medium supplemented with 10% FBS, penicillin (100 IU/
ml), and streptomycin (100 g/ml). Resident macrophages (106 cells)
were infected for 3 h at 37°C with freshly transformed promastigotes, at a
macrophage/promastigote ratio of 1:10. The unphagocytosed parasites
were removed by three washes with medium. Infected macrophages were
then incubated at 37°Cwithmedium containing graded concentrations of
free cationic liposomes. In another experiment, infected macrophages
were incubated with SSG-loaded PC-SA and PC-DDAB liposomes. After
1 h, excess liposomes were removed and the cells were placed in fresh
complete RPMI 1640 medium for an additional 72 h. Cells were then air
dried, fixed in methanol, and stained with Giemsa stain. The numbers of
amastigotes in 200 macrophages in drug-treated and control cultures
were counted microscopically (20).
Isolation of splenic amastigotes. To isolate amastigotes (25), spleens
of infected hamsters were rinsed in ice-cold 20 mM PBS with glucose
(1.8%) and lightly homogenized. Macroscopic particles were allowed to
settle, and the turbid suspension was decanted. This suspension was cen-
trifuged at 100 g for 10 min. The amastigote-enriched suspension was
centrifuged at 800  g for 10 min. The pellet was suspended in 45%
Percoll (4.0 ml), 25% Percoll (2.0 ml) was layered over the amastigote
suspension, and the preparation was centrifuged at 10,000 g for 45min.
The band containing amastigotes was taken, washed with PBS (three
times), and resuspended in RPMI 1640 medium. The freshly isolated
amastigotes (2  105) were incubated with or without recombinant an-
nexin V (2 g/100 l) for 30 min at 26°C and subsequently were treated
with PC-SA or PC-DDAB liposomes (213M) for 1 h at 37°C. The killing
activities were determined with the MTT assay, as described above.
Confocal microscopy. Peritoneal macrophages were isolated and
charged with parasites as described above. To assess the difference in the
uptake of liposomes, infectedmacrophageswere incubatedwith PC-SAor
PC-DDAB liposomes, loaded with fluorescent dyes for 1 h, and washed
three timeswith PBS. The cells were then fixedwith 4% formaldehyde and
mounted in ProLong Gold antifade reagent with 4=,6-diamidino-2-phe-
nylindole (DAPI) (Molecular Probes). The cells were observed with an
Andor spinning-disk live-cell confocal/total internal reflection fluores-
cence (TIRF)microscope (Andor Technology, Belfast, United Kingdom).
The lasers used had wavelengths of 405 nm, 488 nm, and 561 nm.
Electron microscopy. Transmission electron microscopy (TEM) was
carried out with PBS-treated, PC-DDAB-treated, and PC-DDAB-SSG-
TABLE 1 Chemical formulae of cationic lipids
Lipid IUPAC name Chemical formula Molecular wt
CTAB Hexadecyltrimethylammonium bromide C19H42NBr 364.46
DTAB Dodecyltrimethylammonium bromide C15H34NBr 308.35
DDAB Didodecyldimethylammonium bromide C38H80NBr 631
SA Octadecan-1-amine C18H39N 269.5
DOTAP N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride C43H80NO4Cl 698.54
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treated promastigotes (24). Briefly, cells were fixed with 3% glutaralde-
hyde in PBS, postfixed with 1%OsO4 for 1 to 2 h, gradually dehydrated in
ethanol, and finally embedded in Spurr’s resin. Ultrathin sections cut with
a DuPont diamond knife in an ultramicrotome were stained with uranyl
acetate and lead acetate and were observed with a FEI Tecnai G2 Spirit
Bio Twin FP 5018/40 transmission electron microscope (FEI Co.,
Hillsboro, OR).
In vitro and in vivo cytotoxicity assays. Hemolytic assays were car-
ried out with different concentrations of cationic liposomes incubated
with packed human erythrocytes, at a ratio of 1:10 (vol/vol), for 1 h at
37°C (26). The samples were then centrifuged at 800  g for 10 min. By
measuring the optical density at 540 nm in a spectrophotometer, the re-
lease of hemoglobin from lysed erythrocytes was monitored. Controls
used for 0% hemolysis (blank) and 100% hemolysis consisted of erythro-
cytes suspended in PBS and 1% Triton X-100, respectively.
The cytotoxicity of different cationic liposomes for peritoneal macro-
phages was assessed with a lactate dehydrogenase (LDH) assay (27). Ad-
herent macrophages (106 cells) were incubated with different concentra-
tions of cationic liposomes in RPMI 1640 medium for 3 h at 37°C. LDH
activity was determined by measuring the decrease in the absorbance of
NADH at 340 nm in the macrophage supernatants.
Specific enzyme levels related to normal kidney and liver functions
were chosen to determine the in vivo toxic effects of cationic liposomal
formulations. PC-DDABandPC-DDAB-SSGwere injected intravenously
(i.v.) into healthy mice at 5, 8, and 10 mg of PC/mouse in 200 l PBS.
Analyses of serum levels of creatinine, urea, and enzymes such as serum
glutamate pyruvate transaminase (SGPT) and serum alkaline phospha-
tase (ALP) were carried out 15 days after drug administration, using the
respective assay kits.
Infection and treatment. For experimental infections, BALB/c mice
were injected with 2.5 107 hamster spleen-derived L. donovani amasti-
gotes via the tail vein. Eight-week-infected mice (6 or 7 mice per group)
received a single i.v. dose of either free SSG (3 mg/kg body weight), drug-
free PC-DDAB liposomes (5mg of PC/mouse), or PC-DDAB-SSG (75g
SSG, equivalent to 3 mg/kg, associated with 5 mg of PC/mouse). For
comparative evaluation of efficacy, groups of BALB/c mice were treated
with a single injection of 75g of SSG in 5 mg of PC either as PC-DDAB-
SSG or as PC-SA-SSG. At 90 days postinfection, animals were sacrificed,
and liver and spleen parasite burdens were determined by examining
methanol-fixed, Giemsa-stained imprints of the cut organs; results were
expressed as Leishman-Donovan units (LDU), calculated as the number
of amastigotes per 1,000 nucleated cells organ weight (mg) (21). In the
case of bonemarrow, 100l of PBS-flushed bonemarrow suspensionwas
smeared over glass slides, fixed with methanol, and then stained with
Giemsa stain to estimate the number of parasites (21). In selected exper-
iments, limiting dilution assayswere performed, inwhich homogenates of
liver and spleen were serially diluted and cultured for 2 weeks. Parasite
burdenswere expressed as the total number of parasites per organ, and the
mean values for parasite burdens in three mice were calculated (21).
In vivo immunomodulatory activity. Healthy mice were injected
with PC-SA-SSG or PC-DDAB-SSG at the indicated doses, via the tail
vein. At 10 days postinjection, splenocytes were isolated and incubated as
described earlier (28). Concentrations of gamma interferon (IFN-) and
interleukin 10 (IL-10) were measured in the culture supernatants in re-
sponse to stimulation with concanavalin A (ConA) and lipopolysaccha-
ride (LPS) (25), respectively, by sandwich enzyme-linked immunosor-
bent assay (ELISA) (BD Pharmingen kit), as recommended by the
manufacturer. In another set of experiments, splenocytes from differently
treated mice were cultured overnight and stained with fluorochrome-
labeled antibodies against CD4, CD8, CD19, IFN-, and IL-10 (28). Data
were acquired in a FACSCanto cell analyzer (Becton Dickinson) and an-
alyzed with FACSDiva software.
Statistical analysis.Data are expressed as means standard errors of
the mean; 50% inhibitory concentration (IC50) values were calculated as
50% inhibitory concentrations for suppression of parasite growth by sig-
moidal regression analysis, using Microsoft Excel 2007. Statistical differ-
ences between two groups were determined with Student’s t test, and
differences between multiple groups were determined using one-way
analysis of variance (ANOVA) followed by Tukey’s multiple-comparison
test. P values of0.05 were considered significant.
RESULTS
Liposome formulations and characterization. Size measure-
ments of the diluted liposomes formed with various cationic lip-
ids, performed on the day of preparation, indicated average diam-
eters of 252.0 39.77 nm, 299.7 23.76 nm, 197.6 10.25 nm,
303.8  35.22 nm, and 240.3  79.25 nm for PC-CTAB, PC-
DTAB, PC-DDAB, PC-SA, and PC-DOTAP, respectively, with no
significant differences between the vesicles (P  0.05) (Table 2).
All liposomes were of heterogeneous size, and their polydispersity
indices varied between 0.2 and 0.4. The sizes remained consistent
for 4 weeks for all liposomes except for PC-DTAB, which showed
an increase, probably due to aggregation. The zeta potentials of
PC-CTAB, PC-DTAB, PC-DDAB, PC-SA, and PC-DOTAP lipo-
somes were 23.2 3.9mV, 20.3 4.4mV, 33.6 8.4mV, 23.5
6 mV, and 18.5  2.1 mV, respectively (Table 2). The greatest
electrophoretic mobility of PC-DDAB correlated with its highest
zeta potential.
Antileishmanial activity of cationic liposomes against L.
donovani promastigotes. We reported previously that SA-bear-
ing liposomes (PC-SA) had potent antileishmanial activity (18,
19). To determine whether liposomes prepared with other cat-
ionic lipids also had antiparasitic effects, cationic liposomes at
graded concentrations were incubated for 1 h with both SSG-
sensitive AG83 and SSG-resistant GE1F8R and CK1R strains of
promastigote cultures. Of the five cationic liposome types evalu-
ated, PC-CTAB and PC-DOTAP had no appreciable antiparasitic
effects, even at concentrations as high as 213 M, for both AG83
and GE1F8R (Fig. 1). In contrast, PC-DTAB and PC-DDAB were
found to have appreciable leishmanicidal activity. PC-SA and PC-
DDABwere nearly equipotent at higher doses, tested against both
strains of L. donovani. At concentrations of 213 M, these lipo-
somes induced85% killing of L. donovani promastigotes, com-
pared to PBS treatment. The IC50 values of PC-SA and PC-DDAB
forAG83promastigoteswere 20 and 24Mand those forGE1F8R
were 52 and 70 M, respectively (Table 3). For CK1R, all of the
liposomes had high IC50s (80 M), with PC-DDAB being most
effective at 81.21 M.
Cationic liposomes elicit antileishmanial activity against in-
tracellular amastigotes. Treatment of infectedmacrophages with
various cationic liposomes resulted in dose-dependent killing ofL.
donovani amastigotes of both SSG-sensitive and SSG-resistant
strains by all of the liposomes (Fig. 2). PC-SA, PC-DDAB, and
PC-DTAB induced effective inhibition of parasite growth. Results
TABLE 2 Physicochemical properties of cationic liposomes
Formulation
Particle diameter
(nm)
Zeta potential
(mV)
Electrophoretic
mobility
(V/cm)
PC-CTAB 252.0 39.77 23.2 3.9 5.5
PC-DTAB 299.7 23.76 20.3 4.4 4.5
PC-DDAB 197.6 10.25 33.6 8.4 16.7
PC-SA 303.8 35.22 23.5 6 15
PC-DOTAP 240.3 79.25 18.5 2.1 2.5
Sinha et al.
346 aac.asm.org January 2015 Volume 59 Number 1Antimicrobial Agents and Chemotherapy
 o
n
 O
ctober 20, 2016 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
demonstrated that infected macrophages treated with PC-DDAB
showed remarkable reductions in parasite burdens (96% and 91%
for AG83 and GE1F8R, respectively), compared to macrophages
treatedwith PC-SA (89% and 81% for AG83 andGE1F8R, respec-
tively), after 72 h of incubation at a dose of 213 M (P  0.05).
Based on the IC50s, PC-DDAB had 2- and 1.7-fold greater efficacy
than PC-SA liposomes against AG83 and GE1F8R amastigotes,
respectively (Table 3). Amastigotes of the clinical isolate CK1R
were much more susceptible to cationic liposomes, with PC-
DDAB, PC-DTAB, and PC-CTAB being more effective than
PC-SA and PC-DOTAP. PC-DDAB showed an IC50 of 16.10 M,
a value 5-fold greater than the IC50 for PC-SA. In an MTT-based
viability study using freshly isolated splenic amastigotes (AG83),
we showed that the parasites were more susceptible to PC-DDAB
than PC-SA and the activities were reversed by annexin V treat-
ment to almost the same extents (see Fig. S1 in the supplemental
material).
Uptake of liposomes into infected macrophages. Fig. 2C
shows PC-SA (Fig. 2C, left) and PC-DDAB (Fig. 2C, right) lipo-
somes inside infected macrophages. We microscopically visual-
ized the intracellular fates of PC-SA and PC-DDAB liposomes by
labeling themembranewith rhodamine B (red) and encapsulating
the green dye 5-carboxyfluorescein (green). Intact liposomes (yel-
low) were seen inside the infected macrophages (nuclei stained
blue), close to the amastigotes (small dots stained blue). Although
we did not observe any significant differences in the uptake of
liposomes at the initial time points (data not shown), liposomes
bearing DDAB showed a more diffuse appearance at 2 h after
treatment, whereas PC-SA appeared more punctate (Fig. 2C). It
appears from the images that PC-DDAB liposomes interact better
with the amastigotes, resulting in faster disintegration and release
of their contents, as we could see the diffused green dye in the
cytoplasm. In the case of PC-SA, most of the liposomes appeared
intact, with the dye entrapped, at the same time point. Another
interesting observation was that liposomes were preferentially
taken up by infectedmacrophages versus uninfectedmacrophages
(data not shown), probably due to changes in phagocytic behavior
after infection (29). From these observations, it can be inferred
that PC-DDABcould serve as an effective carrier of SSG andmight
deliver the drug to intracellular amastigotes better than PC-SA
liposomes.
Ultrastructural alterations induced by PC-DDAB-SSG. Elec-
tron microscopic analysis demonstrated many alterations in the
ultrastructure of promastigotes treated with PC-DDAB and PC-
DDAB-SSG formulations. In contrast to untreated parasites (Fig.
3A), promastigotes treated with a 75% inhibitory concentration
dose of PC-DDAB appeared with increased intracellular vacuol-
ization (Fig. 3B). However, parasites treated with an equivalent
dose of PC-DDABwith incorporated SSGbecame completely per-
meated, as manifested by a loss of electron-dense intracellular
space and a loss of the shapes of cytoplasmic organelles (Fig. 3C).
This effect could be caused by alterations in the physicochemical
properties of the membrane system of the parasites, making them
more susceptible to disruption. The ultrastructural alterations did
TABLE 3 In vitro antileishmanial activity of cationic liposomes
Formulation
IC50 (M)
Promastigotes Amastigotes
AG83 GE1F8R AG83 GE1F8R
PC-CTAB 510 4 220 9 62 0.5 230 0.5
PC-DTAB 53 12.8 83 8.2 92 3.2 43 1.3
PC-DDAB 24 17.4 70 1.6 27 0.5a 40 0.8a
PC-SA 20 33.9 52 5 53 2.4 70 1.6
PC-DOTAP 180 2.2 456 6 216 0.1 436 0.7
a P 0.05, compared to PC-SA.
FIG 1 Leishmanicidal activity of graded concentrations of various cationic
liposomes against promastigotes of the SSG-responsive strain AG83 (A) and
the SSG-resistant strain GE1F8R (B), at 22°C. Values are means  standard
errors of three independent experiments performed in duplicate.
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not pinpoint any specific primary site of action of PC-DDAB-SSG
onpromastigotes, although it is likely that the parasitemembranes
are affected.
Toxicity assays.Considering the profound antileishmanial ac-
tivity of PC-DDAB, which was even better than that of PC-SA, we
proceeded to perform toxicity screening tests that are routinely
used in drug development programs to determine the safety of the
drug. The cytotoxic effects toward murine macrophages and hu-
man erythrocytes were measured with LDH and red blood cell
(RBC) lysis assays. All of these liposomes were nontoxic in the
therapeutic range of doses (see Table S1 in the supplemental ma-
terial). Further in vivo toxicity studies were carried out with the
PC-DDAB liposomes by estimating serum ALP and SGPT levels
(specific enzymes related to liver dysfunction) and serumurea and
creatinine levels (related to kidney dysfunction) at 15 days after
injection of therapeutic aswell as higher doses of liposomes, which
demonstrated levels within the normal ranges (data not shown),
indicating no toxicity under the given conditions.
Combination therapy with suboptimal SSG doses in PC-
DDAB liposomes showed enhanced antileishmanial efficacy. A
single suboptimal dose of SSG (3 mg/kg), both in free form and
entrapped in PC-DDAB liposomes (5 mg PC/mouse), and empty
PC-DDAB (5 mg PC/mouse) were administered intravenously to
60-day-infected BALB/cmice. The animals were sacrificed 30 days
posttreatment to analyze the therapeutic potentiality against both
SSG-sensitive AG83 and SSG-resistant GE1F8R L. donovani infec-
tions (Fig. 4) (20). Free SSG could suppress AG83 infection by
only 26% in the liver and 10% in the spleen, with almost no activ-
ity against parasites in the bone marrow. Lower levels of parasites
were observed in the group treated with only PC-DDAB vesicles
(85%, 82%, and 68.4% suppression of liver, spleen, and bonemar-
row parasite burdens, respectively; P  0.05), in comparison to
untreated infected controls. Of the three therapies, combined
therapy with SSG within PC-DDAB resulted in maximal inhibi-
tion, with 96.4%, 99.6%, and 86% suppression of AG83 parasite
burdens in liver, spleen, and bonemarrow, respectively (Fig. 4A to
C). More importantly, PC-DDAB-SSG formulations could also
mount successful activity against SSG-resistant GE1F8R L. don-
ovani parasites, suppressing parasite burdens in liver, spleen, and
bone marrow by 97.9%, 96.5%, and 84.4%, respectively, whereas
free SSGwas completely unsuccessful (Fig. 4D to F). The decreases
in spleen and bonemarrow parasite burdens induced by the com-
bination therapy were significantly greater (P 0.05) than those
seen with only vesicles against both AG83 and GE1F8R strains. In
addition, PC-DDAB-SSG-cured mice exhibited significant de-
creases (P 0.05) in the liver and spleen weights, compared with
untreated infected mice (Fig. 4A to D). These data indicate that
therapy with SSG in PC-DDAB vesicles could overcome SSG re-
sistance and also the natural failure of BALB/c mice to contain
parasites in the visceral organs, particularly in the spleen and bone
marrow, organs that are generally refractory to a broad range of
chemotherapeutic interventions.
Comparativeantileishmanial activitiesof liposomalSSGfor-
mulations. Recently we showed that PC-SA-SSG could cure es-
tablished VL irrespective of SSG sensitivity (21). To assess better
therapeutic options against established VL, a comparative study
between PC-DDAB-SSG and previously reported PC-SA-SSG
liposomal formulations was performed with an SSG-sensitive
strain. The in vitro antileishmanial activities of graded doses of
both cationic liposomal formulationswere analyzed.We observed
FIG 2 (A and B) Effects of graded concentrations of various cationic liposomes
on L. donovani amastigote proliferation within murine peritoneal macro-
phages, using the AG83 (A) and GE1F8R (B) strains. Values are means 
standard errors of three independent experiments. (C) Uptake of PC-SA (left)
and PC-DDAB (right) liposomes inside infected macrophages. Peritoneal
macrophages isolated from BALB/c mice were infected with L. donovani pro-
mastigotes for 3 h and subsequently treated with fluorescent PC-SA or PC-
DDAB liposomes.Macrophage nuclei are stainedwithDAPI (large blue areas).
Intact liposomes are visible close to the amastigote nuclei, colocalizing green
and red fluorescence and appearing yellow. Arrows, L. donovani amastigotes
(small blue areas) inside macrophages. Magnification, 40. Data are repre-
sentative of two independent experiments.
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that PC-DDAB-SSG therapy was significantly more efficient than
PC-SA-SSG treatment, with 8.8 M lipids in PC-DDAB-SSG for-
mulations suppressing 70% of the parasite burden, in contrast to
33% observed with PC-SA-SSG (P  0.001) (Fig. 5A). The IC50
calculated for PC-DDAB-SSG was 6.3 M lipid. A 2-fold higher
dose of PC-SA-SSG could induce an equivalent effect.
To determine which cationic vesicles synergized better with
SSG against in vivo infections with L. donovani, 60-day-infected
BALB/c mice were subjected to treatment with PC-SA-SSG and
PC-DDAB-SSG liposomal formulations and the levels of protec-
tion were evaluated 30 days posttreatment (Fig. 5B). Seventy-five
micrograms of SSG within PC-DDAB vesicles at 5 mg PC/mouse
significantly induced 105-fold and 104-fold greater suppression of
liver and spleen parasitic burdens, respectively, compared to treat-
ment with an equivalent dose of PC-SA-SSG (P 0.0001), dem-
onstrating that SSG encapsulated in PC-DDAB vesicles is more
efficacious than PC-SA liposomes in suppressing liver and spleen
infections with AG83 parasites.
Immunomodulatory activity of PC-DDAB-SSG. We reported
previously that, in addition to direct killing of the parasites, PC-SA-
SSG at a dose of 20 mg PC/mouse could effectively downregulate
proparasitic IL-10 levels and induce IFN- production from spleno-
cytes, providing a host immune status favorable for cure (21). To
evaluate whether PC-DDAB-SSG at 5 mg PC/mouse could be as ef-
fective as PC-SA-SSG at a dose of 20 mg PC/mouse to bring about
positive immunomodulation, we injected healthy BALB/cmice with
SSG entrapped in PC-SA or PC-DDAB (5mg PC/mouse) and com-
pared the results with those obtained with our previously reported
therapeutic dose, as mentioned above. All of the liposomal treat-
ments showed significant decreases in IL-10 levels and upregulation
of IFN- levels (P 0.001, one-wayANOVA) (Fig. 6A andB). Inter-
estingly,healthymice treatedwithPC-DDAB-SSGat5mgPC/mouse
demonstrated effective downregulation of IL-10 levels and concom-
itant upregulation of IFN- levels, which were comparable to the
responses observed with a 4 times higher dose of PC-SA-SSG (P
0.05). The IFN- response observed with PC-SA-SSG at 5 mg PC/
mouse was comparatively weaker, and although IL-10 production
was suppressed to an appreciable extent, the IFN- upsurge was sig-
nificantly greater in the PC-DDAB-SSG-treated animals (P 
0.0001). Flow cytometric analysis revealed that IFN- production
from CD4 and CD8 cells increased significantly (P 0.05, one-
way ANOVA) in all treated groups, with comparable IFN- produc-
tion with PC-SA-SSG at 20 mg PC/mouse and PC-DDAB-SSG at 5
mg PC/mouse (Fig. 6C and D). Interleukin 10 production from
CD4 and CD8 T cells and CD19 B cells decreased in all treated
mice, compared to untreated controls (Fig. 6E toG), with significant
decreases in CD4 and CD19 cells (P 0.05, one-way ANOVA).
The decrease in IL-10 levels from CD4 cells observed with PC-
DDAB-SSG at 5 mg PC/mouse was again comparable to that ob-
served with PC-SA-SSG at 20 mg PC/mouse. Additionally, the de-
creases in intracellular IL-10 levels fromCD4Tcellswere significant
for both PC-DDAB-SSG-treated and high-dose PC-SA-SSG-treated
healthy mice, compared with low-dose PC-SA-SSG-treated mice
(P  0.05) (Fig. 6E). We also checked the ability of our liposomal
therapy to induce delayed-type hypersensitivity (DTH) reactions in
infected hosts posttreatment. PC-DDAB and PC-DDAB-SSG
showed strong DTH reactions in response to leishmanial antigen,
with PC-DDAB being themajor contributor. The difference in foot-
pad swelling between PC-DDAB and PC-DDAB-SSG was insignifi-
cant, however (data not shown).
FIG 3 Electron microscopic assessment of L. donovani promastigotes treated
with free and SSG-encapsulated PC-DDAB. (A) Control promastigotes dem-
onstrate an elongated body and a normal aspect of the intracellular organelles.
(B) The 75% effective dose (ED75) of PC-DDAB induced vacuolization and
alterations at the plasma membrane. (C) Parasites treated with the ED75 of
PC-DDAB incorporating SSGwere spherical, with a complete absence of elec-
tron-densematerials. Bars, 2m (magnification,30,000) (A and B) or 1m
(magnification,60,000) (C). Nu, nucleus; Mt, mitochondria; K, kinetoplast;
FP, flagellar pocket; DMt, dilated mitochondria; FN, fragmented nucleus; V,
vacuoles; dM, dilated matrix of mitochondria; G, granules; MB, membrane
blebbing.
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DISCUSSION
We first compared the physicochemical properties of the lipo-
somes. The tissue distributions and immune-potentiating prop-
erties of liposomes depend on their size (9, 30–32). Since all of the
liposomes were of similar sizes, we could not draw any correla-
tions between their sizes and efficacies. Therefore, we next
checked whether any major differences existed in the charges of
the liposomes, which may account for differences in antiparasitic
activities. Inhibition of parasite growth was previously shown to
be associated with the positive charge of the liposomes (18). Our
attempt to correlate physical properties of the cationic liposomes
with potent antileishmanial activity indicated that the presence of
positive charge paralleled the optimal leishmanicidal efficiency.
PC-DDAB liposomes showed the highest zeta potential and elec-
trophoretic mobility, which correlated best with its antiparasitic
activity, followed by PC-SA. We had previously studied the antil-
eishmanial activity of PC-SA liposomes (21). Therefore, all of the
liposomes were compared with respect to PC-SA for equivalent or
better activity.
Among all of the vesicles tested, liposomes composed of double
alkyl chains, i.e., DTAB and DDAB, showed significant antileish-
manial activity like PC-SA against both promastigotes and intra-
cellular amastigotes of L. donovani strains AG83 and GE1F8R.
Promastigotes of the clinically isolated strain CK1R were almost
equally susceptible, but interestingly the intracellular amastigotes
displayed much higher levels of susceptibility to the liposomes,
compared toGE1F8R. All bromide-containing cationic liposomes
demonstrated potent activity against intracellular amastigotes,
with PC-DDAB being the most effective. Unsaturated lipid
DOTAP-containing liposomes failed to show effective killing of
Leishmania promastigotes as well as amastigotes. Earlier reports
showed CTAB to be a better antibacterial agent than DDAB,
FIG 4 In vivo antileishmanial activity of free and SSG-encapsulated PC-DDAB liposomes. (A, B, D, and E) Therapeutic effects of drugs were analyzed as
reductions in weight and Leishman-Donovan units (LDU) in liver (A and D) and spleen (B and E) of AG83-infected (A and B) and GE1F8R-infected (D and E)
mice. (C and F) Bone marrow parasite loads of AG83 (C) and GE1F8R (F) were expressed as amastigotes per 1,000 bone marrow nuclei. Values are means
standard errors (n	 5) of two independent experiments. , P 0.05 versus control for organ weight and versus PC-DDAB for LDU, by ANOVA.
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which may be due to the more bulky nature of DDAB (33). As
Leishmania parasites are larger than bacteria and have a mem-
brane structure that exposes negatively charged lipids on their
surfaces, DDAB may be better suited for interactions with their
membranes for subsequent killing. Cationic liposomes probably
interact withmacrophage surface receptors (34) and subsequently
are endocytosed by them (35). Inside the macrophages, these cat-
ionic liposomes probably exert dual effects by interacting directly
with the intracellular parasites and also activating macrophage
microbicidal activity. Both PC-SA and PC-DDAB localized close
to the amastigotes when observedmicroscopically, but PC-DDAB
could more efficiently interact and elicit responses. The bulk of
cationic charge on DDAB may contribute to this activity. Leish-
mania membranes consist of multiple polar and nonpolar lipids
(36), which contribute to the surface charges. The difference in the
susceptibility of promastigotes and amastigotes may be due to
differences in the compositions of their plasma membranes (37).
Freshly isolated splenic amastigotes were more susceptible to PC-
DDAB treatment than PC-SA treatment, and treatment with an-
nexin V reversed this activity, implicating a role of negatively
charged membrane phosphatidylserine (PS), although contribu-
tions of other negatively charged components cannot be ruled out.
PS is expressed on the surface of infective Leishmania, and PS
exposure has been reported to correlate with infectivity (38, 39).
Thus, anti-PS killing activity through cationic liposomes can pro-
vide an effective strategy to combat the disease.
In our earlier studies, both L. donovani strain GE1F8R, selected
in the laboratory for SSG resistance, and strain CK1R, a resistant
clinical isolate (IC50 values of 100 g/ml for both strains),
showed equivalent rates of death in response to PC-SA-SSG treat-
ment (21). The strain-independent activity was due to increased
retention of the drug inside the parasites. Although multiple
mechanisms are involved in rendering the parasites unresponsive
to pentavalent antimonials both in vitro and in clinical settings
(40–43), the ultimate reason for nonaction of drugs is decreased
uptake or poor retention in the parasite. Although we observed
some differences in susceptibility of the two strains to cationic
liposomes, PC-DDAB was found to be consistently efficacious to-
ward the isolates. The resistance mechanism in the laboratory-
developed GE1F8R strain was studied by Mookerjee Basu et al.
(42). Infection with GE1F8R induces the upregulation of multi-
drug resistance protein 1 (MRP1) and permeability glycoprotein
in host cells, resulting in nonaccumulation of intracellular SSG
following treatment with SSG, favoring parasite replication (42).
A role of the aquaglyceroporin (AQP) family of genes in the up-
take of antimonials has also been reported for some L. donovani
isolates (43). The studies indicate that, while downregulation of
AQP1 may be one of the mechanisms of antimony resistance, it is
not an invariable feature of such resistance, particularly in the case
of GE1F8R (44). Although the resistance mechanisms of CK1R
have not been studied in detail, the differences in expression levels
of proteins responsible for influx and/or efflux of the drug may
account for the difference in susceptibility observed by us (44).
Interestingly, our liposomal formulation bypasses the strain-to-
strain variations in susceptibility to SSG. The cationic liposomes
cause depletion of cytosolic ATP (45), rendering the efflux pumps
ineffective. Moreover, liposomes containing DDAB form a more
rigid structure than SA in association with helper lipid PC, which
allows longer retention and slow release of the drug for sustained
activity (46).
Cationic liposomes have often been associated with cytotoxic-
ity. The liposomes used here were potentially nontoxic at thera-
peutic doses, suggesting their suitability for further studies. There-
fore, we proceeded to perform in vivo efficacy studies with free and
drug-entrapped liposomes. The in vivo data indicated that therapy
with 3 mg/kg body weight SSG in PC-DDAB vesicles could over-
come the natural failure of BALB/c mice to contain parasites not
only in the liver but also in the spleen and bone marrow, organs
generally refractory to a broad range of chemotherapeutic inter-
ventions (4, 5). The antileishmanial activity results suggested syn-
ergistic activity of SSG in combination with PC-DDAB. To our
knowledge, there has been no report of such profound antileish-
manial activity with such a low dose of the drug encapsulated in
liposomes, against SSG-sensitive and -resistant parasites. Success-
ful therapy of VL is accompanied by antiparasitic immunity and
prevention of relapse and reinfection.We report here that 75g of
SSG in merely 5 mg PC/mouse of PC-DDAB could effectively
downregulate proparasitic IL-10 levels, providing a favorable im-
mune status in the host. Recent studies by Mukherjee et al. (47)
show increased IL-10 secretion and resultantMDR1 upregulation
in SSG-resistant clinical isolates. In light of this finding, we may
propose that liposomal SSG reverses this situation in favor of the
FIG 5 Comparative analysis of therapeutic efficacies of PC-SA-SSG versus
PC-DDAB-SSG formulations against L. donovaniAG83 infections. (A) In vitro
leishmanicidal activity was documented as the number of amastigotes in 200
macrophages after 72 h of treatment. Data represent means of three indepen-
dent experiments performed in triplicate. (B) Suppression of liver and spleen
parasite burdens in 3-month-infected and treated BALB/c mice. Data repre-
sent means  standard errors (n 	 5) of total parasites per organ. , P 
0.001 by Student’s t test (A) or P 0.0001 by ANOVA (B).
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FIG 6 ELISA (A and B) and fluorescence-activated cell sorting analysis (C to G) of splenocytes from normal BALB/c mice treated with PC-SA-SSG or
PC-DDAB-SSG. (A and B) Splenocytes were isolated from mice treated with PC-SA-SSG or PC-DDAB-SSG liposomes and were cultured for determination of
IFN- (A) and IL-10 (B) levels. (C to G) Splenocytes treated with PC-SA-SSG or PC-DDAB-SSG were gated for CD4 (C and E), CD8 (D and F), and CD19
(G) cells and permeabilized, and intracellular IFN- (C and D) and IL-10 (E, F, and G) levels were determined. Data represent means standard errors (n	 4).
, P 0.0001; , P 0.05.
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host. Antiparasitic IFN- secretion is the key to clearance of infec-
tion and establishment of host protection (48). Liposomes con-
taining saturated lipids preferably induce Th1-type immune re-
sponses (49) and DDAB is a known IFN- inducer (50). High
concentrations of this cytokine in mice treated with PC-DDAB-
SSG strengthen our claim for its profound leishmanicidal activity.
Previously we observed synergism between PC-SA and SSG for
IL-10 suppression in vitro (21). In the present study, however, we
compared the therapeutically active dose of PC-DDAB-SSG with
an equivalent dose of PC-SA-SSG.
The antiparasitic activity of positively charged SA-bearing lipo-
somes was well observed against Toxoplasma, Trypanosoma, and
Leishmania parasites (18, 19, 51, 52), and this might be attributed
to charge-based interactions of cationic liposomes with negatively
charged membranes of parasites (45, 53, 54), followed by direct
cytotoxic action. Vesicles formed of DDAB exhibited antibacterial
activity against different species of bacteria (55, 56) and fungistatic
activity againstCandida albicans, which were attributed to surface
charge interactions (56, 57). Charge-based interactions were re-
ported for antimicrobial cationic peptides such as magainin 2,
temporins, and CA(1-8)M(1-18) (58, 59), which interact with
pathogenmembranes, leading to degeneration of intracellular or-
ganelles, blurred definition of the boundaries of intracellular or-
ganelles, increases in electron-translucent intracellular space, and
apparent expansion and disruption of membrane structures.
Here, among other vesicles, we have screened DDAB vesicles for
maximal efficacy against Leishmania promastigotes and amasti-
gotes. Experiments with DDAB-containing liposomes have
pointed toward nonionic and hydrophobic interactions with
membrane lipids or the hydrophobic portions of membrane pro-
teins (60), although some degree of ionic interactions with phos-
phate groups of phospholipids and other negatively charged com-
ponents of the membrane cannot be ruled out. It is possible that
the stable binding of DDAB liposomes to parasite membranes
allows the drug to enter inside, adding to the cellular disruption
observed in the electronmicroscopic experiments. Although there
are reports that promastigotes are insensitive to pentavalent anti-
mony, studies show that high concentrations of the drug make
promastigotes sensitive (40, 61). Furthermore, DDAB has been
established as a potent adjuvant, mounting strong cell-mediated
immune responses and proinflammatory reactions (30, 50). The
immunoadjuvant properties of DDAB have been attributed to
longer availability of DDAB-bearing liposomes at the site of injec-
tion and recruitment of monocytes for the generation of effective
immune responses (62). Herein, a strong Th1 immune response
synergizes with the parasite killing to confer better therapeutic
protection to the host. Although the immune reactions that follow
PC-DDAB-SSG therapy remain to be studied, triggering a strong
antiparasitic immune environment in healthy mice injected with
the formulation resulted in favorable modulation of the host im-
mune responses.
Various liposomal formulations of SSG have been reported to
elicit significant leishmanicidal activity in vivo in chronically in-
fected BALB/c mice. Although these formulations demonstrated
spectacular success against liver parasites (4–6, 63), they failed to
perform in spleen (6, 64). Our previous liposomal SSG formula-
tion with cationic SA-bearing liposomes could successfully elim-
inate SSG-sensitive and SSG-resistant parasites from liver, spleen,
and bone marrow. However, these activities were obtained with
the dose of 20 mg PC/mouse. In the present study, we demon-
strated that 75 g of SSG in 5 mg PC/mouse of PC-DDAB was
enough for eradication of parasites from the liver, spleen, and
bonemarrowof the animals. The dose of SSG that could elicit such
potent curative responses in a single administration was only 3
mg/kg bodyweight, 1/100th of the dose of free drug that is optimal
for treatment (64). Such reductions in liposome and drug dosages
may be favorable for the host cells, preventing unnecessary toxic-
ity and attenuating the chances of refractoriness to antimonial
therapy, making PC-DDAB-SSG a prospective antileishmanial
agent.
The results obtained strongly demonstrate the advantages of
using PC-DDAB encapsulating a very low dose of SSG against L.
donovani infections, irrespective of SSG sensitivity. The use of SSG
has been discontinued in India due to the emergence of clinical
resistance. Since our liposomal formulation works by bypassing
the resistance-inducing mechanisms of the parasite, we propose
that this kind of approach can be developed further to increase the
clinical life of SSG and other drugs that are prone to resistance
development.
The liposomal formulation of SSGprepared in PC-DDAB con-
fers cures against SSG-sensitive and SSG-resistant L. donovani in-
fections in BALB/c mice at a suboptimal dose of the drug not
reported earlier. This therapeutic strategy involving efficient tar-
geting and immunomodulation can be utilized for the develop-
ment of safe, single-shot, therapeutic agents not only against
Leishmania infections but also against other parasitic diseases and
cancer, where drug resistance limits the use of various potent ther-
apeutic agents.
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